Compare General Motors Company (GM) vs Hims and Hers Health Inc (HIMS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Motors Company vs Hims and Hers Health Inc — how do they compare? General Motors Company trades at $77.17 (market cap $70.01B), while Hims and Hers Health Inc trades at $35.33 (market cap $8.60B). The key difference: General Motors Company is far larger — about 8.1× Hims and Hers Health Inc's market cap, and General Motors Company pays a 0.93% dividend while Hims and Hers Health Inc pays none. Which is the better fit depends on your goals.
| GM | HIMS | |
|---|---|---|
Market Cap | $70.01B | $8.60B |
Sector | Consumer Cyclical | Health |
52-Week High | $86.38 | $66.18 |
52-Week Low | $48.89 | $14.52 |
Enterprise Value | $173.34B | $8.98B |
Dividend Yield | 0.93% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Motors (GM) trades at $76.87, up 0.2% daily, with a neutral technical signal. The company shows strong operational cash flow of $26.87B in 2025 and has beaten earnings estimates for three consecutive quarters. Valuation metrics appear attractive with P/S of 0.4 and P/B of 1.12, while analyst consensus remains bullish with a $102 price target representing 33% upside potential.
GM presents a value opportunity with depressed valuation multiples despite recent earnings beats and solid cash generation. Key risks include declining profit margins (1.38% net margin in 2025), competitive pressures in the EV transition, and elevated debt levels. The stock's appeal hinges on margin stabilization and successful execution of strategic initiatives amid industry headwinds.
Hims & Hers Health trades at $35.52, up 1.05% today, with a bullish technical signal from moving averages and a consensus analyst price target of $33.57. Recent earnings show volatility with a Q1 2026 miss, but revenue grew to $2.35 billion in 2025. The company benefits from expansion in weight-loss therapies and a $400 million JPMorgan facility, though high valuations like a P/E of 57.14 and negative net income margin pose concerns.
Outlook is mixed: growth opportunities in telehealth and GLP-1 drugs support upside, but earnings inconsistency and regulatory risks from FDA reviews require caution. Analysts are 35% buy-rated, highlighting potential if execution improves, yet investors face volatility near key resistance at $38.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About General Motors Company
General Motors Co. emerged from the bankruptcy of General Motors Corp. (old GM) in July 2009. GM has eight brands and operates under four segments: GM North America, GM International, Cruise, and GM Financial. The United States now has four brands instead of eight under old GM. The company lost its U.S. market share leader crown in 2021 with share down 280 basis points to 14.6%, but we expect GM to reclaim the top spot in 2022 as 2021 suffered from the chip shortage. GM Financial became the company's captive finance arm in October 2010 via the purchase of AmeriCredit.
Read more on GM →About Hims and Hers Health Inc
Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →
